Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation

HELIUS MEDICAL TECHNOLOGIES, INC. (HSDT) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/07/2021 GN Helius Medical Technologies, Inc. to Release First Quarter of Fiscal Year 2021 Financial Results on May 17, 2021
03/29/2021 GN Helius Medical, Inc Receives U.S. Marketing Authorization for the PoNS™ Device
03/17/2021 GN Helius Medical Technologies, Inc. to Present at the Investor Summit Group's Q1 Virtual Summit on March 23rd
03/17/2021 GN Helius Medical Technologies, Inc. Appoints Sherrie Perkins to its Board of Directors
02/02/2021 GN Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 10, 2021
02/01/2021 GN Helius Medical Technologies, Inc. Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
01/20/2021 GN Helius Medical Technologies, Inc. Comments on the Centers for Medicare & Medicaid Services' Announcement Regarding New Medicare Coverage Pathway for Breakthrough Medical Devices
01/19/2021 GN Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards
01/11/2021 GN Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis
01/04/2021 GN Helius Medical Technologies, Inc. to Present at Four Upcoming Investor Conferences in January
12/31/2020 GN Helius Medical Technologies, Inc. Announces Reverse Stock Split
11/05/2020 GN Helius Medical Technologies, Inc. to Present at Upcoming Investor Conferences in November
11/04/2020 GN Helius Medical Technologies, Inc. Announces the Expansion to a Total of 27 Authorized PoNS Treatment™ Clinic Locations Across Canada
11/02/2020 GN Helius Medical Technologies to Release Third Quarter of Fiscal Year 2020 Financial Results on November 12, 2020
10/26/2020 GN Helius Medical Technologies Announces Closing of $3.4 Million Private Placement
10/21/2020 GN Helius Medical Technologies Announces $3.4 Million Private Placement
10/19/2020 GN Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis
10/14/2020 GN Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights
10/08/2020 GN Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board
09/08/2020 GN Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury
08/31/2020 GN Helius Medical Technologies, Inc. to Present at Three Upcoming Investor Conferences in September
08/25/2020 GN Helius Medical Technologies, Inc. Announces Departure of President, Chief Executive Officer and Chairman Philippe Deschamps; Board of Directors Appoints Dane C. Andreeff as Interim President and Chief Executive Officer and Appoints Blane Walter as Chairman of the Board of Directors
08/12/2020 GN Helius Medical Technologies, Inc. Reports Second Quarter of Fiscal Year 2020 Financial Results
08/10/2020 GN Helius Medical Technologies to Release Second Quarter of Fiscal Year 2020 Financial Results on August 12, 2020
08/06/2020 GN Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020
06/15/2020 GN INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Helius Medical Technologies, Inc. for Potential Breach of Fiduciary Duty Claims
06/05/2020 GN Helius Medical Technologies to Present at the Virtual Summer Summit on June 9th
05/12/2020 GN Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis
04/30/2020 GN UPDATE -- Helius Medical Technologies, Inc. Announces Publication of its PoNS??? Registrational Clinical Trial (TBI-001) in TBI
04/22/2020 GN Helius Medical Technologies to Release First Quarter of Fiscal Year 2020 Financial Results on May 7, 2020
04/22/2020 GN Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors
03/24/2020 GN Helius Medical Technologies Announces Authorization from Health Canada to Market the PoNS™ Device for the Treatment of Gait Deficit Due to Mild and Moderate Multiple Sclerosis (MS)
03/18/2020 GN Helius Medical Technologies Announces $2.2 Million Registered Direct Offering
03/09/2020 GN Helius Medical Technologies, Inc. Provides Details on Five Recently Authorized PoNS Treatment™ Clinics
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy